San Diego-based Crinetics Pharmaceuticals, focused on endocrine-related cancers and endocrine disorders, appointed Alan Krasner as chief medical officer.

Krasner joins Crinetics from Shire Pharmaceuticals, where he was a senior medical director and served as global development lead for the hormone treatment Natpara. Prior to Shire, he worked at Biodel and Pfizer conducting clinical research at various stages of development in diabetes and obesity.

He holds undergraduate and M.D. degrees from Northwestern University and received his clinical training in Internal Medicine and Endocrinology at Johns Hopkins University.

In March, Crinetics raised $63.5 million through a series B financing round.